Document Detail

Influenza A (H5N1) pandemic prototype vaccine Fluval.
MedLine Citation:
PMID:  19397418     Owner:  NLM     Status:  MEDLINE    
The timely development of safe and effective vaccines is likely to be the single most important public-health tool for decreasing the morbidity, mortality and economic effects of the influenza pandemic. The objective of this article is to provide a detailed description of the chemistry and immunogenicity of one of the better studied inactivated whole-virion aluminum phosphate-adjuvanted vaccines, Fluval (Omninvest, Hungary), while we discuss safety data of all clinical trials published on H5N1 vaccines to date. Fluval was chosen for detailed discussion owing to its immunogenicity after only one dose, the fact that it was one of the very first H5N1 vaccines that demonstrated the potential for dose sparing and, unlike all mainstream oil-in-water adjuvanted reverse genetics-derived H5N1 vaccines, it is whole virion based.
Zoltan Vajo
Related Documents :
911018 - A perspective on the significance of pandemic influenza.
15962218 - Multinational impact of the 1968 hong kong influenza pandemic: evidence for a smolderin...
19453438 - A pilot study of the immune response to whole inactivated avian influenza h7n1 virus va...
16298028 - Highly pathogenic avian influenza (h7n7): vaccination of zoo birds and transmission to ...
22145028 - Pre-clinical assessment of novel multivalent msp3 malaria vaccine constructs.
23953808 - Variability in the immune system: of vaccine responses and immune states.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert review of vaccines     Volume:  8     ISSN:  1744-8395     ISO Abbreviation:  Expert Rev Vaccines     Publication Date:  2009 May 
Date Detail:
Created Date:  2009-04-28     Completed Date:  2009-05-22     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101155475     Medline TA:  Expert Rev Vaccines     Country:  England    
Other Details:
Languages:  eng     Pagination:  619-24     Citation Subset:  IM    
University of Debrecen, Medical and Health Science Center, Debrecen, Hungary.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adjuvants, Immunologic / pharmacology
Aluminum Compounds / pharmacology
Disease Outbreaks / prevention & control
Influenza A Virus, H5N1 Subtype / genetics,  immunology*
Influenza Vaccines / adverse effects*,  genetics,  immunology*
Influenza, Human / epidemiology,  prevention & control
Phosphates / pharmacology
Vaccines, Inactivated / adverse effects,  genetics,  immunology
Reg. No./Substance:
0/Adjuvants, Immunologic; 0/Aluminum Compounds; 0/Influenza Vaccines; 0/Phosphates; 0/Vaccines, Inactivated; 13765-93-0/aluminum phosphate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines.
Next Document:  Update on Campylobacter jejuni vaccine development for preventing human campylobacteriosis.